{"protocolSection":{"identificationModule":{"nctId":"NCT02047344","orgStudyIdInfo":{"id":"GHNSCLC-2 001"},"organization":{"fullName":"Golden Biotechnology Corporation","class":"INDUSTRY"},"briefTitle":"Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC","officialTitle":"A Single-Arm, Open-Label, Phase II Trial Evaluating the Efficacy, Safety and Pharmacokinetics of Antroquinonol in Patients With Stage IV (Including Pleural Effusion) Non Squamous NSCLC Who Have Failed Two Lines of Anti-Cancer Therapy"},"statusModule":{"statusVerifiedDate":"2019-12","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2013-10"},"primaryCompletionDateStruct":{"date":"2018-12-07","type":"ACTUAL"},"completionDateStruct":{"date":"2018-12-07","type":"ACTUAL"},"studyFirstSubmitDate":"2014-01-16","studyFirstSubmitQcDate":"2014-01-26","studyFirstPostDateStruct":{"date":"2014-01-28","type":"ESTIMATED"},"resultsFirstSubmitDate":"2019-09-16","resultsFirstSubmitQcDate":"2019-12-11","resultsFirstPostDateStruct":{"date":"2019-12-26","type":"ACTUAL"},"lastUpdateSubmitDate":"2019-12-11","lastUpdatePostDateStruct":{"date":"2019-12-26","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Golden Biotechnology Corporation","class":"INDUSTRY"},"collaborators":[{"name":"ICON Clinical Research","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"This is a single arm, open label, Phase II study in KRAS-positive and KRAS-negative patients with stage IV (including pleural effusion) non squamous NSCLC who have failed two lines of anti-cancer therapy. A maximum of 60 evaluable patients with NSCLC will receive antroquinonol, of which 30 patients will be KRAS-positive and 30 patients KRAS-negative. An evaluable patient will have received at least one dose of antroquinonol and have a valid baseline tumor assessment. Enrollment will continue until the target number of evaluable patients has been enrolled.","detailedDescription":"1. Progression free survival rate at 12 weeks, defined as the proportion of patients alive and progression free at Week 12. Patients will be progression free if they have no tumor assessments of progressive disease (defined according to RECIST guidelines, version 1.1) at any point from the start of treatment to Week 12.\n2. Objective response rate (ORR), defined as the proportion of patients whose best overall response is either CR or PR according to RECIST version 1.1. The best overall response is the best response recorded during the first 12 week treatment cycle.\n3. Disease control rate (DCR), defined as the proportion of patients with a documented CR, PR and SD during the first 12 week treatment cycle according to RECIST version 1.1.\n4. Duration of overall tumor response (DR), defined as the interval between the date of the first observation of tumor response (CR or PR) and the date of disease progression or death.\n5. Progression free survival defined as the time from randomization to objective tumor progression by RECIST version 1.1 or death due to any cause, whichever occurs first.\n6. Overall survival (OS) defined as the time from randomization to death from any cause.\n7. Time to progression (TTP) defined as the time from randomization to objective tumor progression by RECIST version 1.1."},"conditionsModule":{"conditions":["Non-small Cell Lung Cancer Stage IV"],"keywords":["NSCLC"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":31,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Antroquinonol (Hocena)","type":"EXPERIMENTAL","description":"patients will receive one 12 week cycle of antroquinonol 200 mg t.i.d. or until disease progression, unacceptable toxicity, non compliance or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever comes first.","interventionNames":["Drug: Antroquinonol"]}],"interventions":[{"type":"DRUG","name":"Antroquinonol","description":"patients will receive one 12 week cycle of antroquinonol 200 mg t.i.d. or until disease progression, unacceptable toxicity, non compliance or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever comes first.","armGroupLabels":["Antroquinonol (Hocena)"],"otherNames":["Hocena"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Progression Free Survival Rate","description":"Tumor response will be assessed at 6 week intervals during the first treatment cycle using the RECIST criteria, version 1.1. Each patient will be assigned one of the following categories: 1) complete response (CR), 2) partial response (PR), 3) stable disease (SD), or 4) progressive disease (PD). Patients who died from any cause or discontinued the study for any reason without a post screening or Week 12 tumor assessment will be considered as failing to respond to treatment.","timeFrame":"12 weeks"}],"secondaryOutcomes":[{"measure":"Cmax","description":"PK sampling will be performed on Days 0 and 28 in all patients enrolled in Stage 1.PK endpoints will be derived for intensively sampled PK profiles by non compartmental methods and include: Cmax: peak concentration;Ctrough: trough plasma concentration.","timeFrame":"8 hours"},{"measure":"Disease Control Rate (DCR)","description":"the proportion of patients with a documented CR, PR and SD during the first 12 week treatment cycle according to RECIST version 1.1.","timeFrame":"12 weeks"},{"measure":"T½: the Time Required for a Quantity to Reduce to Half Its Initial Value","description":"PK sampling will be performed on Days 0 and 28 in all patients enrolled in Stage 1.PK endpoints will be derived for intensively sampled PK profiles by T½: terminal half life","timeFrame":"8 hours"}],"otherOutcomes":[{"measure":"Objective Response Rate (ORR)","description":"Defined as the proportion of patients whose best overall response is either CR or PR according to RECIST version 1.1. The best overall response is the best response recorded during the first 12 week treatment cycle.","timeFrame":"12 weeks"},{"measure":"Overall Survival","description":"the time from the date of first administration of study drug to death from any cause","timeFrame":"up to week 48"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Cytologically or histologically confirmed non squamous NSCLC Stage IV (including pleural effusion).\n* Radiologically confirmed disease progression following two previous lines of anti-cancer therapy, one of which should be a platinum based regimen, OR the patient has refused treatment with approved treatment modalities\n* At least one radiologically measurable target lesion per RECIST version 1.1\n* Fresh or archival biopsy tissue available to determine tumor mutation status\n* Written informed consent that is consistent with International Conference on Harmonisation Tripartite Guideline on Good Clinical Practice guidelines\n* Patient or legally acceptable representative has granted written informed consent before any study specific procedures (including special Screening tests) are performed\n* Eastern Cooperative Oncology Group (ECOG) performance score of 0, 1 or 2\n* Hemoglobin ≥ 9.0 g/dL; platelets ≥ 100 x 109/L; absolute neutrophil count ≥ 1.5 x 109/L without the use of hematopoietic growth factors\n* Bilirubin and creatinine less than 2 × upper limit of normal (ULN) for the institution\n* Albumin ≥ 2.5 mg/dL\n* Aspartate aminotransferase and alanine aminotransferase less than 5 × ULN for the institution\n* Prothrombin time less than 1.5 × ULN for the institution\n* Potassium, magnesium and phosphorus within the normal range for the institution (supplementation is permissible)\n* Recovery to Grade 1 or baseline of any toxicities due to prior treatments, excluding alopecia\n\nExclusion Criteria:\n\n* Chemo-, hormone- or immunotherapy, within 4 weeks or within less than four half lives of the date of first administration of study drug and/or persistence of toxicities of prior anti-cancer therapies which are deemed to be clinically relevant\n* Radiotherapy within the past 2 weeks prior to date of first administration of study drug\n* Previous treatment with an histone deacetylase inhibitor or an epidermal growth factor receptor inhibitor within at least 4 weeks of the date of first administration of study drug\n* Treatment with any drug(s) known to be an inhibitor or inducer of cytochrome P450 (CYP)2C19, CYP3A4, CYP2C8, and CYP2E1, within 14 days of the date of first administration of study drug\n* Brain metastases, which are symptomatic; patients with treated, brain metastases are eligible with stable brain disease for at least 4 weeks without the requirement for steroids or anti epileptic therapy\n* Inability to swallow oral medications or a recent acute gastrointestinal disorder with diarrhea e.g., Cohn's disease, malabsorption, or Common Terminology Criteria for Adverse Event (CTCAE) Grade \\> 2 diarrhea of any etiology at baseline\n* Other malignancies diagnosed within the past five years (other than curatively treated cervical cancer in situ), non melanoma skin cancer, superficial bladder tumors Ta (non invasive tumor) and TIS (carcinoma in situ)\n* Patients with any serious active infection (i.e., requiring an intravenous antibiotic, antifungal, or antiviral agent)\n* Patients with known human immunodeficiency virus, active hepatitis B or active hepatitis C\n* Patients who have any other life threatening illness or organ system dysfunction, which in the opinion of the investigator, would either compromise patient safety or interfere with the evaluation of the safety of the study drug\n* Known or suspected substance abuse or alcohol abuse\n* Pregnancy or breast feeding\n* History of clinically significant or uncontrolled cardiac disease, including congestive heart failure, angina, myocardial infarction, arrhythmia, including New York Heart Association functional classification of three","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Howard Cheng, Ph.D.","affiliation":"Golden Biotechnology Corp.","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Arizona Clinical Research Center","city":"Tucson","state":"Arizona","zip":"85715","country":"United States","geoPoint":{"lat":32.22174,"lon":-110.92648}},{"facility":"UCSF","city":"San Francisco","state":"California","zip":"94115","country":"United States","geoPoint":{"lat":37.77493,"lon":-122.41942}},{"facility":"Rush University Medical Center","city":"Chicago","state":"Illinois","zip":"60612","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"John Hopkins University","city":"Baltimore","state":"Maryland","zip":"21287","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"Peninsula Regional Med Center","city":"Salisbury","state":"Maryland","zip":"21801","country":"United States","geoPoint":{"lat":38.36067,"lon":-75.59937}},{"facility":"Henry Ford health system","city":"Detroit","state":"Michigan","zip":"48202","country":"United States","geoPoint":{"lat":42.33143,"lon":-83.04575}},{"facility":"Guthrie Clinic, Ltd","city":"Sayre","state":"Pennsylvania","zip":"18840","country":"United States","geoPoint":{"lat":41.97896,"lon":-76.5155}},{"facility":"Chang Gung Memorial Hospital-Kaohsiung medical center","city":"Kaohsiung City","zip":"88301","country":"Taiwan","geoPoint":{"lat":22.61626,"lon":120.31333}},{"facility":"National Cheng Kung University Hospitail","city":"Tainan","zip":"704","country":"Taiwan","geoPoint":{"lat":22.99083,"lon":120.21333}},{"facility":"Tri Service General Hospital","city":"Taipei","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}}]},"ipdSharingStatementModule":{"ipdSharing":"NO","description":"need DMC proved"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Written informed consent was obtained from all patients before initiating screening. The screening period was up to 42 days in duration (Days 42 to 1) for K-Ras testing result, if no history k-Ras result.","recruitmentDetails":"Unselected KRAS-positive and KRAS-negative patients with stage IV (including pleural effusion) non squamous NSCLC and radiologically-confirmed disease progression following greater than or equal to two, but less than or equal to four, prior lines of systemic anti cancer therapy.","groups":[{"id":"FG000","title":"K-Ras Negative","description":"Fresh or archival biopsy tissue to determine KRAS is not mutant."},{"id":"FG001","title":"K- Ras Mutant","description":"Fresh or archival biopsy tissue to determine KRAS is mutant."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","comment":"one patient is not evaluable in process. however, evaluable to safety report.","numSubjects":"16"},{"groupId":"FG001","numSubjects":"15"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"16"},{"groupId":"FG001","numSubjects":"15"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"K-Ras Negative","description":"Fresh or archival biopsy tissue to determine KRAS is not mutant. Patients will receive one 12 week cycle of antroquinonol 200 mg t.i.d. or until disease progression."},{"id":"BG001","title":"K- Ras Mutant","description":"Fresh or archival biopsy tissue to determine KRAS is mutant. Patients will receive one 12 week cycle of antroquinonol 200 mg t.i.d. or until disease progression."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"30"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"9"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"21"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"11"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"19"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Asian","categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"9"}]}]},{"title":"Black or African American","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}]}]},{"title":"White","categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"19"}]}]}]},{"title":"Region of Enrollment","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"21"}]}]},{"title":"Taiwan","categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"9"}]}]}]},{"title":"ECOG performance status","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"title":"Fully active","categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"11"}]}]},{"title":"Restricted in physically strenuous activity","categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"16"}]}]},{"title":"Capable of all selfcare more than 50% work","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Progression Free Survival Rate","description":"Tumor response will be assessed at 6 week intervals during the first treatment cycle using the RECIST criteria, version 1.1. Each patient will be assigned one of the following categories: 1) complete response (CR), 2) partial response (PR), 3) stable disease (SD), or 4) progressive disease (PD). Patients who died from any cause or discontinued the study for any reason without a post screening or Week 12 tumor assessment will be considered as failing to respond to treatment.","populationDescription":"Defined as the proportion of patients alive and progression free at Week 12.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"12 weeks","groups":[{"id":"OG000","title":"Progression-free Survival Rate/KRAS Negative Group","description":"200mg TID for treating KRAS negative patients 12 weeks"},{"id":"OG001","title":"Progression-free Survival Rate/KRAS Mutant Group","description":"200mg TID for treating KRAS negative patients 12 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"15"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Cmax","description":"PK sampling will be performed on Days 0 and 28 in all patients enrolled in Stage 1.PK endpoints will be derived for intensively sampled PK profiles by non compartmental methods and include: Cmax: peak concentration;Ctrough: trough plasma concentration.","populationDescription":"There were 22 patients with reported concentration data who were eligible for the PK population.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ng/mL","timeFrame":"8 hours","groups":[{"id":"OG000","title":"Antroquinonol (Hocena)","description":"patients will receive one 12 week cycle of antroquinonol 200 mg t.i.d. or until disease progression, unacceptable toxicity, non compliance or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever comes first."},{"id":"OG001","title":"Antroquinonol Day 28","description":"continue use Antroquinonol for 28 Days"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"22"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"276.87","spread":"211.162"},{"groupId":"OG001","value":"393.55","spread":"315.434"}]}]}]},{"type":"SECONDARY","title":"Disease Control Rate (DCR)","description":"the proportion of patients with a documented CR, PR and SD during the first 12 week treatment cycle according to RECIST version 1.1.","populationDescription":"26 patients can be run the full analysis","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"12 weeks","groups":[{"id":"OG000","title":"Non- Prior Chemotherapies","description":"Patient without any chemotherapy before join Study"},{"id":"OG001","title":"One Line Failed Prior Chemotherapies","description":"Patient join with One line failed prior chemotherapies"},{"id":"OG002","title":"Two Lines Failed Prior Chemotherapies","description":"Patients join with two lines failed prior chemotherapies"},{"id":"OG003","title":"More Than Two Lines Failed Prior Chemotherapies","description":"patient failed more than two line chemotherapies before join."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"11"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40","lowerLimit":"5.3","upperLimit":"85.3"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"70.8"},{"groupId":"OG002","value":"42.9","lowerLimit":"9.9","upperLimit":"81.6"},{"groupId":"OG003","value":"72.7","lowerLimit":"39.0","upperLimit":"94.0"}]}]}]},{"type":"SECONDARY","title":"T½: the Time Required for a Quantity to Reduce to Half Its Initial Value","description":"PK sampling will be performed on Days 0 and 28 in all patients enrolled in Stage 1.PK endpoints will be derived for intensively sampled PK profiles by T½: terminal half life","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Inter-Quartile Range","unitOfMeasure":"hours","timeFrame":"8 hours","groups":[{"id":"OG000","title":"Antroquinonol (Hocena)","description":"patients will receive one 12 week cycle of antroquinonol 200 mg t.i.d. or until disease progression, unacceptable toxicity, non compliance or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever comes first."},{"id":"OG001","title":"Antroquinonol Day 28","description":"continue use Antroquinonol for 28 Days"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"22"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","lowerLimit":"0.5","upperLimit":"4"},{"groupId":"OG001","value":"2","lowerLimit":"0.5","upperLimit":"4"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Objective Response Rate (ORR)","description":"Defined as the proportion of patients whose best overall response is either CR or PR according to RECIST version 1.1. The best overall response is the best response recorded during the first 12 week treatment cycle.","populationDescription":"full sey analysis group","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"patients","timeFrame":"12 weeks","groups":[{"id":"OG000","title":"Antroquinonol (Hocena)","description":"patients will receive one 12 week cycle of antroquinonol 200 mg t.i.d. or until disease progression, unacceptable toxicity, non compliance or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever comes first.\n\nAntroquinonol: patients will receive one 12 week cycle of antroquinonol 200 mg t.i.d. or until disease progression, unacceptable toxicity, non compliance or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever comes first."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Overall Survival","description":"the time from the date of first administration of study drug to death from any cause","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"up to week 48","groups":[{"id":"OG000","title":"Non- Prior Chemotherapies","description":"Patient without any chemotherapy before join Study"},{"id":"OG001","title":"One Line Failed Prior Chemotherapies","description":"Patient join with One line failed prior chemotherapies"},{"id":"OG002","title":"Two Lines Failed Prior Chemotherapies","description":"Patients join with two lines failed prior chemotherapies"},{"id":"OG003","title":"More Than Two Lines Failed Prior Chemotherapies","description":"patient failed more than two line chemotherapies before join."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"11"}]}],"classes":[{"title":"week 12","categories":[{"measurements":[{"groupId":"OG000","value":"60","lowerLimit":"12.6","upperLimit":"88.2"},{"groupId":"OG001","value":"100","lowerLimit":"100","upperLimit":"100"},{"groupId":"OG002","value":"100","lowerLimit":"100","upperLimit":"100"},{"groupId":"OG003","value":"90.9","lowerLimit":"50.8","upperLimit":"98.7"}]}]},{"title":"week 48","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG001","value":"100","lowerLimit":"100","upperLimit":"100"},{"groupId":"OG002","value":"28.6","lowerLimit":"4.1","upperLimit":"61.2"},{"groupId":"OG003","value":"39.3","lowerLimit":"7.3","upperLimit":"71.6"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"AEs collected for up to 48 weeks of the study from the time the patient signed the informed consent.","description":"Patients were followed for AEs from the date of informed consent until resolution or stabilization, alternative treatment for NSCLC was started 6 months after last dose of study drug, or loss to follow-up, whichever occurred first. In the event of serious or study drug-related toxicities, the patient was followed until resolution or stabilization. Safety follow up data was collected by telephone contact every 3 months after the EOS visit.","eventGroups":[{"id":"EG000","title":"Antroquinonol (Hocena)","description":"patients will receive one 12 week cycle of antroquinonol 200 mg t.i.d. or until disease progression, unacceptable toxicity, non compliance or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever comes first.","deathsNumAffected":14,"deathsNumAtRisk":31,"seriousNumAffected":12,"seriousNumAtRisk":31,"otherNumAffected":31,"otherNumAtRisk":31}],"seriousEvents":[{"term":"Cardiac disorders","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Atrial fibrillation Cardiac arrest Tachycardia","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":31}]},{"term":"Gastrointestinal disorders","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Diarrhoea Intestinal obstruction","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":31}]},{"term":"General disorders and administration site conditions","organSystem":"General disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Death Disease progression","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":31}]},{"term":"Infections and infestations","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Pneumonia Pyelonephritis acute","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":31}]},{"term":"Metabolism and nutrition disorders","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Dehydration Hyponatraemia","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":31}]},{"term":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Malignant neoplasm progression Metastases to central nervous system","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":31}]},{"term":"Nervous system disorders","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Dizziness","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":31}]},{"term":"Renal and urinary disorders","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Haematuria Hydronephrosis Ureteric stenosis Urinoma","stats":[{"groupId":"EG000","numEvents":4,"numAffected":2,"numAtRisk":31}]},{"term":"Respiratory, thoracic and mediastinal disorders","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Acute respiratory failure Dyspnoea Pulmonary oedema Respiratory distress","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":31}]}],"otherEvents":[{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":2,"numAtRisk":31}]},{"term":"Gastrointestinal disorders","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Abdominal pain Abdominal pain upper Diarrhoea Flatulence Nausea Vomiting","stats":[{"groupId":"EG000","numEvents":30,"numAffected":30,"numAtRisk":31}]},{"term":"General disorders and administration site conditions","organSystem":"General disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Catheter site pain Chest pain Fatigue Influenza like illness","stats":[{"groupId":"EG000","numEvents":20,"numAffected":20,"numAtRisk":31}]},{"term":"Infections and infestations","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Pneumonia","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":31}]},{"term":"Investigations","organSystem":"Investigations","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Urine analysis abnormal Weight decreased","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":31}]},{"term":"Metabolism and nutrition disorders","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Decreased appetite Dehydration Hypomagnesaemia","stats":[{"groupId":"EG000","numEvents":11,"numAffected":11,"numAtRisk":31}]},{"term":"Musculoskeletal and connective tissue disorders","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Musculoskeletal pain Pain in extremity","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":31}]},{"term":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Malignant neoplasm progression","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":31}]},{"term":"Nervous system disorders","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Dizziness Headache Neuropathy peripheral","stats":[{"groupId":"EG000","numEvents":11,"numAffected":11,"numAtRisk":31}]},{"term":"Psychiatric disorders","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Insomnia","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":31}]},{"term":"Renal and urinary disorders","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Haematuria","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":31}]},{"term":"Respiratory, thoracic and mediastinal disorders","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Acute respiratory failure Cough Dyspnoea Nasal congestion Pleural effusion Pneumothorax","stats":[{"groupId":"EG000","numEvents":17,"numAffected":17,"numAtRisk":31}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Howard Cheng","organization":"Golden Biotechnology Corp.","email":"howard@goldenbiotech.com","phone":"+886-2-28086006"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2017-12-06","uploadDate":"2019-09-04T01:53","filename":"Prot_000.pdf","size":1411823},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2014-08-08","uploadDate":"2019-09-04T01:57","filename":"SAP_001.pdf","size":791364}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C545357","term":"antroquinonol"}]}},"hasResults":true}